Parenteral iron use in the management of anemia in end-stage renal disease patients
- 31 January 2000
- journal article
- review article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 35 (1), 1-12
- https://doi.org/10.1016/s0272-6386(00)70294-0
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Erythropoietin and iron use in peritoneal dialysis patients: Report from the 1997 HCFA end-stage renal disease core indicators projectAmerican Journal of Kidney Diseases, 1999
- Safety Aspects of Parenteral Iron in Patients with End-Stage Renal DiseaseDrug Safety, 1997
- Mathematical Approach for Estimating Iron Needs in Hemodialysis Patients on Erythropoietin TherapyAmerican Journal of Nephrology, 1997
- Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agentsAmerican Journal of Kidney Diseases, 1996
- Intravenous Ferric Saccharate as an Iron Supplement in Dialysis PatientsNephron, 1996
- Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patientsThe Lancet, 1994
- Safe Administration of Iron Dextran to a Patient Who Reacted to the Test DoseSouthern Medical Journal, 1994
- Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitorJournal of Allergy and Clinical Immunology, 1994
- Intravenous Fe-Gluconate-Na for Iron-Deficient Patients on HemodialysisNephron, 1992
- Dextran hypersensitivityImmunology Today, 1982